Technical Analysis for BSGM - BioSig Technologies, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 1.11 | 4.72% | 0.05 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Calm After Storm | Range Contraction | 4.72% | |
| Upper Bollinger Band Walk | Strength | 4.72% | |
| Inside Day | Range Contraction | 4.72% | |
| Wide Bands | Range Expansion | 4.72% | |
| Overbought Stochastic | Strength | 4.72% | |
| Upper Bollinger Band Touch | Strength | 4.72% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 24 hours ago |
| Rose Above Previous Day's High | about 24 hours ago |
| Up 3% | about 24 hours ago |
| Up 2% | about 24 hours ago |
| Down 1% | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/11/2024
BioSig Technologies, Inc. Description
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias: Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP(TM) System in August 2018.
Classification
Sector: Healthcare
Industry: Medical Devices
Keywords: FDA Catheter Ablation Cardiac Electrophysiology Technology Development Cardiac Arrhythmia Signal Processing Electrophysiology Physiology Atrial Fibrillation Arrhythmia Circulatory System Cardiovascular System Processing Technology Catheter Ablation Tachycardia Ventricular Tachycardia Topera Medical
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.89 |
| 52 Week Low | 0.201 |
| Average Volume | 182,086 |
| 200-Day Moving Average | 1.67 |
| 50-Day Moving Average | 0.48 |
| 20-Day Moving Average | 0.52 |
| 10-Day Moving Average | 0.73 |
| Average True Range | 0.12 |
| RSI (14) | 78.35 |
| ADX | 47.82 |
| +DI | 40.10 |
| -DI | 10.53 |
| Chandelier Exit (Long, 3 ATRs) | 0.77 |
| Chandelier Exit (Short, 3 ATRs) | 0.58 |
| Upper Bollinger Bands | 1.17 |
| Lower Bollinger Band | -0.13 |
| Percent B (%b) | 0.95 |
| BandWidth | 250.32 |
| MACD Line | 0.15 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.1048 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.21 | ||||
| Resistance 3 (R3) | 1.20 | 1.16 | 1.20 | ||
| Resistance 2 (R2) | 1.16 | 1.13 | 1.16 | 1.19 | |
| Resistance 1 (R1) | 1.13 | 1.11 | 1.14 | 1.14 | 1.18 |
| Pivot Point | 1.09 | 1.09 | 1.09 | 1.09 | 1.09 |
| Support 1 (S1) | 1.06 | 1.06 | 1.08 | 1.08 | 1.04 |
| Support 2 (S2) | 1.02 | 1.04 | 1.02 | 1.03 | |
| Support 3 (S3) | 1.00 | 1.02 | 1.02 | ||
| Support 4 (S4) | 1.01 |
